NasdaqGS:TERNPharmaceuticals
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
Terns Pharmaceuticals (TERN) is back in focus after revising its agreement with Hansoh. The company has shifted to an exclusive, sublicensable, royalty-bearing, perpetual license for TERN-701 outside Greater China, alongside supportive interim Phase 1 data.
See our latest analysis for Terns Pharmaceuticals.
The agreement revision and positive interim Phase 1 data come after a sharp 90 day share price return of 102.42% and a very large 1 year total shareholder return. However, the 30 day share...